Angiomotin-L2 Inhibitors
Angiomotin-L2 inhibitors constitute a diverse group of chemicals that modulate the activity of Angiomotin-L2 through indirect mechanisms. These compounds target specific pathways and cellular processes, leading to the inhibition of Angiomotin-L2 within intricate signaling networks. Verteporfin, a photosensitizer, indirectly inhibits Angiomotin-L2 by disrupting the Hippo signaling pathway. It activates YAP/TAZ degradation, impacting the expression and function of Angiomotin-L2 within the Hippo pathway and subsequently leading to its inhibition. Dasatinib, a tyrosine kinase inhibitor, indirectly inhibits Angiomotin-L2 by targeting Src family kinases, disrupting downstream signaling pathways. Y-27632, a selective Rho-associated protein kinase (ROCK) inhibitor, indirectly inhibits Angiomotin-L2 through the regulation of actin cytoskeleton dynamics. FAK Inhibitor 14 targets Focal Adhesion Kinase (FAK), indirectly inhibiting Angiomotin-L2 through the disruption of FAK-mediated signaling pathways. Rapamycin, an mTOR inhibitor, indirectly inhibits Angiomotin-L2 by disrupting the mTOR signaling pathway.
Sorafenib, a multi-kinase inhibitor, indirectly inhibits Angiomotin-L2 by targeting various kinases involved in angiogenesis and cellular signaling. Fasudil, a Rho-kinase inhibitor, indirectly inhibits Angiomotin-L2 by targeting Rho-kinase and modulating downstream signaling pathways. PF-562271, a focal adhesion kinase (FAK) inhibitor, disrupts FAK-mediated signaling pathways, leading to the modulation of Angiomotin-L2 expression and function. Additionally, compounds targeting the YAP-TEAD interaction and statins, influencing cholesterol biosynthesis and cellular signaling, provide further insights into the intricate regulatory mechanisms governing Angiomotin-L2 inhibition within cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Verteporfin | 129497-78-5 | sc-475698 sc-475698A | 10 mg 100 mg | $354.00 $2764.00 | 5 | |
Verteporfin, a photosensitizer, indirectly inhibits Angiomotin-L2 by disrupting the Hippo signaling pathway. It activates YAP/TAZ degradation, impacting the expression and function of Angiomotin-L2 within the Hippo pathway and subsequently leading to its inhibition. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a tyrosine kinase inhibitor, indirectly inhibits Angiomotin-L2 by targeting Src family kinases. By disrupting the activation of Src, Dasatinib modulates downstream signaling pathways, influencing Angiomotin-L2 expression and function within cellular processes associated with Src-mediated pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632, a selective Rho-associated protein kinase (ROCK) inhibitor, indirectly inhibits Angiomotin-L2 through the regulation of actin cytoskeleton dynamics. By targeting ROCK, Y-27632 influences cellular processes that impact Angiomotin-L2, leading to its modulation within the context of actin cytoskeleton-associated pathways. | ||||||
FAK Inhibitor 14 | 4506-66-5 | sc-203950 sc-203950A | 10 mg 50 mg | $109.00 $238.00 | 86 | |
FAK Inhibitor 14, targeting Focal Adhesion Kinase (FAK), indirectly inhibits Angiomotin-L2 through the disruption of FAK-mediated signaling pathways. This inhibitor influences downstream events that impact Angiomotin-L2 expression and function within cellular processes associated with FAK-related pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly inhibits Angiomotin-L2 by disrupting the mTOR signaling pathway. It modulates downstream events that influence Angiomotin-L2 expression and function within cellular processes associated with mTOR-mediated pathways, leading to its inhibition. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a multi-kinase inhibitor, indirectly inhibits Angiomotin-L2 by targeting various kinases involved in angiogenesis and cellular signaling. Through the modulation of these kinases, Sorafenib influences Angiomotin-L2 expression and function within cellular processes associated with angiogenesis and related pathways. | ||||||
PF-562271 | 717907-75-0 | sc-478488 sc-478488A sc-478488B | 5 mg 10 mg 50 mg | $312.00 $474.00 $1124.00 | 3 | |
PF-562271, a focal adhesion kinase (FAK) inhibitor, indirectly inhibits Angiomotin-L2 by disrupting FAK-mediated signaling pathways. This inhibitor influences downstream events that impact Angiomotin-L2 expression and function within cellular processes associated with FAK-related pathways, leading to its modulation. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib, a tyrosine kinase inhibitor, indirectly inhibits Angiomotin-L2 by targeting specific tyrosine kinases. By disrupting these kinases, Imatinib modulates downstream signaling pathways, influencing Angiomotin-L2 expression and function within cellular processes associated with these tyrosine kinase-mediated pathways. | ||||||